Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection

Table 2

Patients with vitamin D < 10 ng/mL at baseline. Objective vitamin D > 20 ng/mL. Univariate and multivariate analysis.

	Univariate analysis			Multivariate analysis
	Objective yes: 69 (82.1%); (%)	Objective no: 15 (17.9%); (%)		OR (95% CI)
VitD supplements
Yes	60 (96.8)	2 (3.2)	0.0001	66.76 (10.06–442.85)	0.0001
No	9 (40.9)	13 (59.1)
TDF exposure				0.33 (0.05–1.92)	0.22
Yes	32 (84.2)	6 (15.8)	0.65
No	37 (80.4)	9 (19.6)
NNRTI exposure				1.12 (0.69–18.38)	0.93
Yes	26 (76.5)	8 (23.5)	0.26
No	43 (86)	7 (14)
PIs exposure				0.19 (0.01–2.97)	0.23
Yes	42 (89.4)	5 (10.6)	0.08
No	27 (73)	10 (27)